by Paul | 8th July 2026 | News
FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company’s clinical development program for urcosimod Company unveils NEPTUNE (Neuropathic Eye Pain Treatment with Urcosimod & Nerve...
by Paul | 7th July 2026 | News
London and New York, NY, July 7, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced...
by Paul | 19th May 2026 | News
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO’s introduction to the broader ophthalmology community at ASCRS drove strong engagement at Eyecelerator and ARVO London and New...
by Paul | 29th April 2026 | News
Robert J. Dempsey, MBA, Chief Executive Officer, to present at Eyecelerator Raj Patil, PhD, Chief Scientific Officer, to present at ARVO London and New York, NY, April 29, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing...
by Paul | 7th April 2026 | News
London and New York, NY, April 7, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it...
by Paul | 19th March 2026 | News
London and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has...
